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Editors: Anton N. Sidawy and Bruce A. PerlerAgreement between site-reported and ultrasound core
laboratory results for duplex ultrasound velocity
measurements in the Carotid Revascularization
Endarterectomy versus Stenting Trial
R. Eugene Zierler, Kirk W. Beach, Robert O. Bergelin, Brajesh
K. Lal, Wesley S. Moore, Gary S. Roubin, Jenifer H. Voeks,
and Thomas G. Brott, for the CREST Investigators
Objective: Patients in the Carotid Revascularization Endar-
terectomy vs Stenting Trial (CREST) had duplex ultrasound
(DU) scans prior to treatment and during follow-up to docu-
ment the severity of carotid disease and the anatomic out-
come of carotid endarterectomy (CEA) or carotid artery
stenting (CAS). An ultrasound core laboratory (UCL) reviewed
DU data from the clinical sites. This analysis was done to
determine the agreement between site-reported and UCL-
veriﬁed DU velocity measurements.
Methods: Clinical site DU worksheets, B-mode images,
and Doppler velocity waveforms for the treated carotid
arteries were reviewed at the UCL. The highest internal
carotid artery peak systolic velocity (PSV) and associated
Doppler angle were veriﬁed. If the angle was misaligned by
>3 degrees, it was remeasured at the UCL and the PSV was
recalculated. Agreement for PSV was deﬁned as site-
reported PSV within ±5% of UCL-veriﬁed PSV. Transcription
errors were corrected by the UCL but were not considered
as disagreements. Follow-up analysis was limited to pa-
tients who received the assigned treatment.
Results: The UCL reviewed 1702 prior-to-treatment and
1743 12-month follow-up DU scans (873 CEA, 870 CAS) from
111 clinical sites. Site-reported and UCL-veriﬁed PSV agreed
in 1124 (66%) of the prior-to-treatment scans and 1200
(69%) of the follow-up scans. In those cases with a dis-
agreement, Doppler angle accounted for disagreement in
339 (59%) of the prior-to-treatment scans and 277 (51%) of
the follow-up scans. Based on a threshold PSV for ≥70%
stenosis of ≥230 cm/s on the prior-to-treatment scans and
≥300 cm/s on the follow-up scans, UCL review resulted in
reclassiﬁcation of stenosis severity in 75 (4.4%) of the prior-
to-treatment scans and 13 (0.75%) of the follow-up scans.
There is evidence that the proportion of reclassiﬁcation at
follow-up was greater for CAS (10 scans; 1.2%) than for CEA
(3 scans; 0.34%) (P = .057).
Conclusions: There was a high rate of agreement be-
tween site-reported and UCL-veriﬁed DU results in CREST,
and UCL review was associated with a low rate of stenosis*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(13)00754-5reclassiﬁcation. However, angle alignment errors were quite
common and prompted recalculation of velocity in 20% of
prior-to-treatment scans and 18% of follow-up scans. The
use of a UCL provides a uniform process for DU inter-
pretation and can identify sources of error and suggest
technical improvements for future studies.Carotid stenting versus endarterectomy in patients
undergoing reintervention after prior carotid
endarterectomy
Margriet Fokkema, Gert Jan de Borst, Brian W. Nolan, Ruby
C. Lo, Robert A. Cambria, Richard J. Powell, Frans L. Moll,
Marc L. Schermerhorn, on behalf of the Vascular Study
Group of New England
Background: Outcomes for patients undergoing inter-
vention for restenosis after prior ipsilateral carotid endarter-
ectomy (CEA) in the era of carotid angioplasty and stenting
(CAS) are unclear. We compared perioperative results and
durability of CAS vs CEA in patients with symptomatic or
asymptomatic restenosis after prior CEA and investigated the
risk of reintervention compared with primary procedures.
Methods: Patients undergoing CAS and CEA for restenosis
between January 2003 andMarch 2012were identiﬁedwithin
the Vascular Study Group of New England (VSGNE) database.
End points included any stroke, death ormyocardial infarction
(MI) within 30 days, cranial nerve injury at discharge, and
restenosis ≥70% at 1-year follow-up. Multivariable logistic
regression was done to identify whether prior ipsilateral CEA
was an independent predictor for adverse outcome.
Results: Out of 9305 CEA procedures, 212 patients (2.3%)
underwent redo CEA (36% symptomatic). Of 663 CAS pro-
cedures, 220 patients (33%) underwent CAS after prior ipsi-
lateral CEA (31% symptomatic). Demographics of patients
undergoing redo CEA were comparable to patients under-
going CAS after prior CEA. Stroke/death/MI rates were sta-
tistically similar between redo CEA vs CAS after prior CEA in
both asymptomatic (4.4% vs 3.3%; P = .8) and symptomatic
patients (6.6% vs 5.8%; P = 1.0). No signiﬁcant difference in
restenosis ≥70% was identiﬁed between redo CEA and CAS
after prior CEA (5.2% vs 3.0%; P = .5). Redo CEA vs primary
CEA had increased stroke/death/MI rate in both symptomatic
(6.6% vs 2.3%; P = .05) and asymptomatic patients 4.4% vs
1.7%; P = .03). Prior ipsilateral CEA was an independent
predictor for stroke/death/MI among all patients undergoing
CEA (odds ratio, 2.1; 95% conﬁdence interval, 1.3-3.5). No
difference in cranial nerve injury was identiﬁed between redo
CEA and primary CEA (5.2% vs 4.7%; P = .8).
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tically equivalent outcomes in asymptomatic and symp-
tomatic patients treated for restenosis after prior ipsilateral
CEA. However, regardless of symptom status, the risk of
reintervention was increased compared with patients un-
dergoing primary CEA.ITER Registry and results of Gore Excluder endograft for
the treatment of elective infrarenal abdominal aortic
aneurysms
Carlo Pratesi, Gabriele Piffaretti, Giovanni Pratesi, Patrizio
Castelli, the ITalian Excluder Registry (ITER) Investigators
Background: To report the midterm results of elective
endovascular aortic repair (EVAR) of abdominal aortic an-
eurysms (AAAs) in a multicenter, clinical unsponsored reg-
istry using the Gore Excluder endograft.
Methods: This study is a retrospective analysis of a multi-
center, prospective registry that involved nine centers in Italy.
Periodic clinical and radiographic follow-up with computed
tomography scans were performed at 1, 6, and 12 months
after the procedure, and on a yearly basis thereafter..
Results: A total of 872 patients underwent elective EVAR.
Primary technical success was 97.5%, and hospital mortality
was 1.0% (9/872). At least 816 (93.6%) patients underwent
a follow-up control. Freedom from all-cause death was esti-
mated to be 97.9% at 1 year, 93.4% at 3 years, and 88.5% at
5 years. Aneurysm-related mortality was 1.6% (n = 13) with
only two late AAA-related deaths observed at 21 and
36 months. Signiﬁcant predictors of all-cause mortality
included age (P < .001) and AAA maximum diameter (P =
.027).Overall conversion ratewas2.3% (n = 19).Meanelapsed
time from initial intervention to surgical conversion was 23 ±
18months (range, 0-52months). Late rupturewas detected in
four (0.5%) cases: two of these patients died after conversion.
The rate of any reinterventionwas 9.4% (n = 77);most of them
were requiredwithin the ﬁrst 24months.The leading cause of
reintervention was endoleak (n = 41; 5.0%). Limb thrombosis
occurred in nine (1.1%) cases. Freedom from reintervention at
1, 3, and 5 years of follow-up were 98.6%, 94.6%, and 86.5%.
Conclusions: The ITalian Gore Excluder Registry is the
largest clinical unsponsored registry using a single device,
with the longest follow-up period so far. The present experi-
ence conﬁrms the effectiveness of EVAR using the Gore
Excluder with low rates of mortality, migration, reinterven-
tion, and limb thrombosis.One-year outcomes from an international study of the
Ovation Abdominal Stent Graft System for endovascular
aneurysm repair
Manish Mehta, Francisco E. Valdés, Thomas Nolte, Gregory
J. Mishkel, William D. Jordan, Bruce Gray, Mark Eskandari
and Charles Botti, on behalf of “A Pivotal Clinical Study to
Evaluate the Safety and Effectiveness of the Ovation
Abdominal Stent Graft System” InvestigatorsObjective: This study evaluated 1-year safety and effec-
tiveness outcomes of the United States regulatory trial for
the Ovation Abdominal Stent Graft System (TriVascular Inc,
Santa Rosa, Calif) for endovascular repair of abdominal
aortic aneurysms (AAAs).
Methods: This prospective, multicenter, single-arm trial
was conducted at 36 sites in the United States, Germany, and
Chile to evaluate the safety and effectiveness of the Ovation
stent graft. From November 2009 to May 2011, 161 patients
(88% males; mean age, 73 ± 8 years) with AAAs (mean
diameter, 54 ± 9 mm) were treated with the Ovation stent
graft. The main body is a modular two-docking limb device
with a 14F outer diameter delivery system, active suprarenal
ﬁxation, and polymer-ﬁlled proximal rings that accommodate
the aortic neck for seal. Main inclusion criteria included
proximal aortic neck length ≥7 mm, inner neck diameter be-
tween 16 and30mm, distal iliac landing zones length ≥10mm,
and diameter between 8 and 20 mm. Patients were treated
under a common protocol, including clinical and imaging fol-
low-up at discharge, 30 days, 6 months, and annually through
5 years. A Clinical Events Committee adjudicated adverse
events, an independent imaging core laboratory analyzed
imaging, and a Data Safety and Monitoring Board provided
study oversight. Complete 1-year follow-up data were avail-
able for this report.
Results: The Ovation stent graft was implanted successfully
in 161 patients (100%), including 69 (42.9%) by percutaneous
access. General anesthesia was used in 106 patients (65.8%).
Technical success was 100%, and mean procedure time was
110 minutes. Median procedural blood loss was 150 mL, and
medianhospital staywas 1day.The 30-daymajor adverse event
rate was 2.5%. At 1 year, AAA-related and all-cause mortality
were 0.6% and 2.5%, respectively. Major adverse event and
serious adverse event rates through 1 year were 6.2% and
38.5%, respectively. The 1-year treatment success rate was
99.3%. The imaging core laboratory reported no stent graft
migration or type I, III, or IV endoleaks. At 1 year, type II
endoleaks were identiﬁed in 34% of patients, and AAA
enlargement was identiﬁed in one patient (0.7%). No AAA
rupture or conversion to open surgery was reported. AAA-
related secondary procedures were performed in 10 patients
(6.2%) for 12ﬁndings, includingendoleak (six), aorticmainbody
stenosis (three), and iliac limb stenosis or occlusion (three).
Conclusions: The 1-year results of the Ovation Abdominal
Stent Graft System demonstrate excellent safety and
effectiveness in treatment of patients with AAAs, partic-
ularly in patients with challenging anatomic characteristics,
including short aortic necks and narrow iliac arteries. Lon-
ger-term follow-up is needed.Utility of direct angiosome revascularization and runoff
scores in predicting outcomes in patients undergoing
revascularization for critical limb ischemia
Marcus R. Kret, David Cheng, Amir F. Azarbal, Erica L.
Mitchell, Timothy K. Liem, Gregory L. Moneta and Gregory J.
Landry
114 AbstractsObjective: Both runoff scores and direct (DR) vs indirect
revascularization (IR) according to pedal angiosomes have
unclear impact on outcome for patients with critical limb
ischemia (CLI). We compared DR vs IR and runoff scores in
CLI patients undergoing infrapopliteal bypass for foot
wounds.
Methods: Patients who had tibial/pedal bypass for a foot/
ankle wound from 2005-2011 were identiﬁed and opera-
tions classiﬁed as DR or IR based on wound location and
bypass target. A blinded observer reviewed angiograms for
an intact pedal arch and calculated standard Society for
Vascular Surgery (single tibial) and modiﬁed (composite
tibial) runoff scores. Comorbidities, wound characteristics,
wound healing, major amputation, and overall survival were
determined.
Results: A total of 106 limbs were revascularized in 97
patients; 54 limbs had DR and 52 had IR, although only 36%
of wounds corresponded to a single, distinct angiosome.
Wound characteristics and comorbidities were similar be-
tween groups. Mean standard (7.9 vs 7.2; P = .001) and
modiﬁed (22.2 vs 20.0; P = .02) runoff scores were worse
(higher number indicates worse runoff) in the IR vs DR
groups; 33% had a complete pedal arch. Complete wound
healing (78% vs 46%; P = .001) and time to complete
healing (99 vs 195 days; P = .002) were superior with DR vs
IR but were not inﬂuenced by runoff score, modiﬁed runoff
score or presence of complete plantar arch. In multivariate
models controlling for runoff score, DR remained a signiﬁ-
cant predictor for wound healing (odds ratio, 2.9; 95%
conﬁdence interval, 1.1-7.4; P = .028) and reduced healing
time (hazard ratio, 2.1; 95% conﬁdence interval, 1.2-3.7; P =
.012). Mean amputation-free survival (75 vs 71 months for
DR vs IR; P = .82) and median survival (36 vs 33 months DR
vs IR; P = .22) were not different for DR vs IR.
Conclusions: DR according to pedal angiosomes provides
more efﬁcient wound healing, but is possible in only one-
half of the patients and does not affect amputation-free or
overall survival. DR is associated with improved runoff
scores, but current runoff scores have little clinical utility in
predicting outcomes in CLI patients.Comparison of surgical bypass with angioplasty and
stenting of superﬁcial femoral artery disease
Mahmoud B. Malas, Ngozi Enwerem, Umair Qazi, Brendan
Brown, Eric B. Schneider, Thomas Reifsnyder, Julie A. Freis-
chlag and Bruce A. Perler
Objective: To evaluate the contemporary outcome of
femoral-popliteal bypass compared with angioplasty and
stenting in patients with symptomatic peripheral arterial
disease (PAD) in terms of patency and reintervention rates.
Methods: We identiﬁed all patients evaluated at the
Johns Hopkins Bayview Medical Center with the presump-
tive diagnosis of PAD from September 2005 to September
2010. In this group, we selected all symptomatic patients
after failing medical management who received percuta-
neous transluminal angioplasty/stenting of the superﬁcialfemoral artery or femoral-popliteal bypass. We compared
the overall patency and reintervention rates between the
two groups as well as patency within TransAtlantic Inter-
Society Consensus (TASC) II subgroups. Descriptive analyses
were performed using χ2 and two-sided t-tests. The Mann-
Whitney U test was used to compare distributions of con-
tinuous variables and the Fisher exact test for categorical
variables. Cox proportional hazard model was used to
examine the treatment effect within each lesion type, using
bypass as the reference group.
Results: Out of 1237 patients evaluated at Johns Hopkins
Bayview Medical Center for PAD from September 2005 to
September 2010, we identiﬁed 104 symptomatic patients
who received percutaneous transluminal angioplasty/
stenting of the superﬁcial femoral artery or femoral-pop-
liteal bypass after failing medical management. There were
61 male patients (56%), and the mean age was 68 years in
both groups. Both treatment groups had similar risk factors.
Overall, 77% of patients with TASC II A and B lesions un-
derwent angioplasty and stenting, whereas 73% of patients
with TASC C and D lesions underwent bypass (P < .01). The
primary patency at 24 months was better for the stent
group 67% (95% conﬁdence interval [CI], 0.52-0.78) vs
bypass group 49% (95% CI, 0.32-0.64; P = .05). The rate of
reintervention within the 2-year period was higher in the
bypass group compared with the stent group (54% vs 31%;
P = .02). TASC A and B lesions combined demonstrated
a reduced hazard of patency failure compared with TASC C
or D lesions combined (hazard ratio, 2.42; 95% CI, 1.26,
4.65; P < .01).
Conclusions: This is the ﬁrst study that documents higher
reintervention rates for femoral-popliteal bypass compared
with angioplasty and stenting. We believe that the main
reason for this ﬁnding is the fact that the bypass patients
had signiﬁcantly more advanced disease. This, emphasizes
that one must consider the patient population undergoing
intervention when comparing revascularization procedures.
A prospective randomized trial is needed to determine the
overall better treatment option.Comparison of open and endovascular treatment of acute
mesenteric ischemia
Robert J. Beaulieu, Dean Arnaoutakis, Christopher J. Abu-
larrage, David T. Efron, Eric Schneider and James H. Black
Introduction: Acute mesenteric ischemia (AMI) is a com-
monly fatal result of inadequate bowel perfusion that re-
quires immediate evaluation by both vascular and general
surgeons. Treatment often involves vascular repair as well
as bowel resection and the possible need for parenteral
nutrition. Little data exist regarding the rates of bowel
resection following endovascular vs open repair of AMI.
Methods: Using the National Inpatient Sample database,
admissions from 2005 through 2009 were identiﬁed ac-
cording to International Classiﬁcation of Diseases, Ninth
Revision codes correlating to both AMI (557.0) and subse-
quent vascular intervention (39.26, 38.16, 38.06, 39.9,
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 1 p. 112e115 January/2014 11599.10). Patients with a diagnosis of AMI but no intervention
or nonemergent admission status were excluded. Patient
level data regarding age, gender, and comorbidities were
also examined. Outcome measures included mortality,
length of stay, the need for bowel resection (45.6, 45.71-9,
45.8), or infusion of total parenteral nutrition (TPN; 99.10)
during the same hospitalization. Statistical analysis was
conducted by χ2 tests and Wilcoxon rank-sum comparisons.
Results: Of 23,744 patients presenting with AMI, 4665 un-
derwent interventional treatment from 2005 through 2009.
Of these patients, 57.1% were female, and the mean age was
70.5 years. A total of 679 patients underwent vascular inter-
vention; 514 (75.7%) underwent open surgery and 165 (24.3%)
underwent endovascular treatment overall during the study
period. The proportion of patients undergoing endovascular
repair increased from 11.9% of patients in 2005 to 30.0% in
2009. Severity of comorbidities, as measured by the Charlson
index, did not differ signiﬁcantly between the treatment
groups. Mortality was signiﬁcantly more commonly associated
with open revascularization compared with endovascular
intervention (39.3% vs 24.9%; P = .01). Length of stay was also
signiﬁcantly longer in the patient group undergoing open
revascularization (12.9 vs 17.1 days; P = .006). During the study
time period, 14.4% of patients undergoing endovascular pro-
cedures required bowel resection compared with 33.4% for
open revascularization (P<.001). Endovascular repair was also
less commonly associated with requirement for TPN support
(13.7% vs 24.4%; P = .025).
Conclusions: Endovascular intervention for AMI had
increased signiﬁcantly in the modern era. Among AMI pa-
tients undergoing revascularization, endovascular treatment
was associated with decreased mortality and shorter length
of stay. Furthermore, endovascular intervention was asso-
ciated with lower rates of bowel resection and need for TPN.
Further research is warranted to determine if increased use
of endovascular repair could improve overall and gastro-
intestinal outcomes among patients requiring vascular repair
for AMI.The Society for Vascular Surgery Lower Extremity
Threatened Limb Classiﬁcation System: Risk stratiﬁcation
based on Wound, Ischemia, and foot Infection (WIfI)
Joseph L. Mills, Michael S. Conte, David G. Armstrong, Frank
B. Pomposelli, Andres Schanzer, Anton N. Sidawy, and
George Andros, on behalf of the Society for Vascular Sur-
gery Lower Extremity Guidelines Committee
Critical limb ischemia, ﬁrst deﬁned in 1982, was intended
to delineate a subgroup of patients with a threatened lower
extremity primarily because of chronic ischemia. It was the
intent of the original authors that patients with diabetes be
excluded or analyzed separately. The Fontaine and Ruth-
erford Systems have been used to classify risk of amputa-
tion and likelihood of beneﬁt from revascularization by
subcategorizing patients into two groups: ischemic rest pain
and tissue loss. Due to demographic shifts over the last
40 years, especially a dramatic rise in the incidence of
diabetes mellitus and rapidly expanding techniques of
revascularization, it has become increasingly difﬁcult to
perform meaningful outcomes analysis for patients with
threatened limbs using these existing classiﬁcation systems.
Particularly in patients with diabetes, limb threat is part of
a broad disease spectrum. Perfusion is only one determi-
nant of outcome; wound extent and the presence and
severity of infection also greatly impact the threat to a limb.
Therefore, the Society for Vascular Surgery Lower Extremity
Guidelines Committee undertook the task of creating a new
classiﬁcation of the threatened lower extremity that reﬂects
these important considerations. We term this new frame-
work, the Society for Vascular Surgery Lower Extremity
Threatened Limb Classiﬁcation System. Risk stratiﬁcation is
based on three major factors that impact amputation risk
and clinical management: Wound, Ischemia, and foot
Infection (WIfI). The implementation of this classiﬁcation
system is intended to permit more meaningful analysis of
outcomes for various forms of therapy in this challenging,
but heterogeneous population.
